ArticleMolecular medicine (Cambridge, Mass.)2026
A novel polymorphism in the TERT gene is associated with lower survival in male patients with melanoma.
Article in Molecular medicine (Cambridge, Mass.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn recent years, several genes beyond BRAF have been identified as recurrently mutated in melanoma, including hTERT (human telomerase reverse transcriptase). While the most extensively studied TERT mutations occur within its promoter region, intron 4 has also been implicated as a locus associated with cancer susceptibility. This study aimed to investigate the role of the rs7734992 polymorphism, located in a potentially functional site within intron 4 of the TERT gene, in melanoma risk and prognosis, as well as to evaluate possible sex-specific effects.
methodsA total of 1,083 melanoma patients with follow-up data exceeding six months were retrospectively included. Genotyping was performed on DNA extracted from peripheral blood using a TaqMan assay.
resultsMale patients carrying the TT genotype of rs7734992 exhibited significantly poorer survival (OR = 3,145, 95% Cis = 1,465—6,753; p = 0.003) compared with females, although no association was found between this polymorphism and melanoma risk.
conclusionsThese findings suggest that the rs7734992 polymorphism may influence melanoma prognosis in male patients. While this study provides novel insights into melanoma genetics, functional investigations are warranted to clarify the biological mechanisms through which rs7734992 could affect male survival, and to explore whether the TT genotype, in conjunction with sex hormone levels, modulates telomerase activity and, consequently, telomere length.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.